Hisamitsu Pharmaceutical Co., Inc.
HTSUF · OTC
2/28/2025 | 2/28/2024 | 2/28/2023 | 2/28/2022 | |
|---|---|---|---|---|
| Revenue | $156,006,000 | $141,706,000 | $128,330,000 | $120,193,000 |
| % Growth | 10.1% | 10.4% | 6.8% | – |
| Cost of Goods Sold | $64,810,000 | $62,735,000 | $55,630,000 | $50,126,000 |
| Gross Profit | $91,196,000 | $78,971,000 | $72,700,000 | $70,067,000 |
| % Margin | 58.5% | 55.7% | 56.7% | 58.3% |
| R&D Expenses | $0 | $8,614,000 | $9,785,000 | $10,613,000 |
| G&A Expenses | $26,526,000 | $25,290,000 | $23,218,000 | $20,582,000 |
| SG&A Expenses | $72,300,000 | $57,189,000 | $51,314,000 | $50,117,000 |
| Sales & Mktg Exp. | $34,871,000 | $31,899,000 | $28,096,000 | $29,535,000 |
| Other Operating Expenses | $1,000 | $1,000 | $0 | $0 |
| Operating Expenses | $72,301,000 | $65,804,000 | $61,099,000 | $60,730,000 |
| Operating Income | $18,895,000 | $13,167,000 | $11,599,000 | $9,337,000 |
| % Margin | 12.1% | 9.3% | 9% | 7.8% |
| Other Income/Exp. Net | $9,792,000 | $6,019,000 | $4,513,000 | $3,618,000 |
| Pre-Tax Income | $28,687,000 | $19,186,000 | $16,113,000 | $12,956,000 |
| Tax Expense | $6,385,000 | $4,754,000 | $3,987,000 | $3,093,000 |
| Net Income | $21,758,000 | $13,969,000 | $11,742,000 | $9,658,000 |
| % Margin | 13.9% | 9.9% | 9.1% | 8% |
| EPS | 295.57 | 181.61 | 148 | 118.92 |
| % Growth | 62.7% | 22.7% | 24.5% | – |
| EPS Diluted | 295.15 | 181.42 | 147.87 | 118.84 |
| Weighted Avg Shares Out | 73,614 | 76,919 | 79,340 | 81,213 |
| Weighted Avg Shares Out Dil | 73,718 | 76,998 | 79,406 | 81,270 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2,748,000 | $2,564,000 | $894,000 | $153,000 |
| Interest Expense | $23,000 | $18,000 | $15,000 | $20,000 |
| Depreciation & Amortization | $6,335,000 | $5,172,000 | $4,952,000 | $4,321,000 |
| EBITDA | $35,045,000 | $24,376,000 | $16,553,000 | $17,297,000 |
| % Margin | 22.5% | 17.2% | 12.9% | 14.4% |